Abstract
The treatment outcome in elderly patients with limited-disease small-cell lung cancer (LD-SCLC) remains poor. We carried out a phase II trial of split topotecan and cisplatin (TP) therapy and sequential thoracic radiotherapy for elderly LD-SCLC patients as a follow-up to our previous phase I trial. In total, 30 patients aged 76years or older, with untreated LD-SCLC were enrolled. Four courses of topotecan (1.0mg/m(2), days 1-3) and cisplatin (20mg/m(2), days 1-3) were administered, followed by thoracic radiotherapy (1.8Gy/day, total of 45Gy). The primary end point was the overall response rate (ORR). The trial was terminated early with 22 patients because of slow accrual. Their median age was 79years. The median number of courses of chemotherapy administered was three, and the actual completion rate of the entire treatment course was 41%. The ORR was 68% with a 95% confidence interval of 47-89% (15/22 cases). The median progression-free survival and overall survival were 9.1 and 22.2months, respectively. The main toxicity was myelosuppression, with grades 3-4 neutropenia (96%), thrombocytopenia (50%), and febrile neutropenia (32%). This regimen produced a favorable survival outcome, despite moderate-to-severe toxicity profiles. Further efforts are necessary to define an optimal regimen for elderly patients with limited SCLC.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call